ArticleAesthetic plastic surgery2026
Experimental and Clinical Evaluation of Optimized Composite Collagen-Crosslinked Hyaluronic Acid Filler for Infraorbital Rejuvenation.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Response to Comments on "Clinical Observations of the Modified Wedge Resection in Composite Labia Minora and Clitoral Hood Reduction Surgery".Aesthetic plastic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTear trough deformity is a prominent periorbital aging manifestation, and minimally invasive filler injection has become a preferred alternative to surgical correction. However, the optimal mixing ratio of collagen (Col) and hyaluronic acid (HA) fillers, as well as refined injection techniques for the delicate infraorbital region, remains a further in-depth investigation.
objectiveTo screen the optimal volume ratio of collagen-HA mixed fillers, verify its anti-photoaging mechanism, and evaluate its clinical efficacy and safety for infraorbital rejuvenation.
methodsA multi-modal study was conducted, the in vitro experiments including cell viability, ROS detection, and ELISA assay for effect of the mix fillers on UV-induced photoaged human dermal fibroblasts (HDFs), as well as the injection forces of the mix fillers. The in vivo study was conducted on UV-induced photoaging mice model with histological, immunofluorescence, and ELISA detections. Additionally, a prospective randomized controlled clinical trial combined with an innovative injection technique was performed to further verify the efficacy and safety of the mix fillers.
resultsIn vitro, the Col/HA (2:1) mix filler treated group showed the highest cell viability, most significant ROS reduction, and strongest collagen synthesis promotion. In vivo, this mix filler effectively alleviated UV-induced skin photoaging, restored collagen and elastic fiber structure and content, suppressed cellular senescence and inflammation. In clinical practice, this mix filler treated group maintained the highest AIHS improvement rate and optimal GAIS scores at 6 months, with the lowest incidence of postoperative complications, such as Tyndall phenomenon, and lumpiness. The other two mix filler (Col/HA(1:1) and Col/HA(1:2)) treated groups exhibited inferior efficacy and safety.
conclusionThe Col/HA (2:1) mix filler, combined with the innovative short fine needle vertical layered injection technique, exhibits excellent anti-photoaging effects and safety, providing a standardized and refined clinical strategy for minimally invasive infraorbital rejuvenation. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42448833What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.